| | | | |

Non-Epithelioid Mesothelioma: Immunotherapy Combo Could be the New Standard of Care

ByAlex Strauss
Non-Epithelioid Mesothelioma

Two immunotherapy drugs could become the new standard of care for people with non-epithelioid mesothelioma. 

All forms of malignant mesothelioma are deadly. But people with a non-epithelioid mesothelioma subtype are less likely to respond to standard treatments. Their variety of mesothelioma is especially resistant to chemotherapy with cisplatin and Alimta. This has been the mainstay of pleural mesothelioma treatment since 2004.

But a new trial shows two immunotherapy drugs extended mesothelioma survival better than chemotherapy. This could be especially good news for patients with non-epithelioid mesothelioma. 

Checkpoint Inhibitors for Mesothelioma

Most people with pleural mesothelioma start with chemotherapy. Chemotherapy can often extend life by a few months. It is most beneficial for patients with epithelioid mesothelioma.

But this approach does not work as well for non-epithelioid mesothelioma. Data presented this week at IASLC’s World Conference on Lung Cancer suggests these patients may have another option. 

The new treatment combines two checkpoint inhibitors. Nivolumab (Opdivo) and ipilimumab (Yervoy) complement each other. They activate the immune system and help keep mesothelioma cells from escaping attack. 

Comparing Chemotherapy & Immunotherapy

The Phase 3 trial is called CheckMate-743. It included 303 patients with epithelioid or non-epithelioid mesothelioma. All patients were inoperable and had not yet had any treatments. 

One group of patients received chemotherapy with cisplatin and pemetrexed (Alimta). Another group received immunotherapy with Opdivo and Yervoy.

For the first eight months, patients in the chemotherapy group seemed to do better. But then the paths switched. At 12 months, 68 percent of the immunotherapy patients were still alive. Fifty-eight percent of the chemotherapy patients were alive. 

At two years, 41 percent of the immunotherapy group was alive, compared to 27 percent of the chemotherapy group. 

Non-Epithelioid Mesothelioma Patients Benefited Most

Immunotherapy was especially helpful for non-epithelioid mesothelioma patients. These patients had an overall survival of just 8.8 months with chemotherapy. Epithelioid mesothelioma patients in the chemotherapy group lived for more than 16 months. 

Lead Investigator Paul Bass, MD, PhD, of the Netherlands Cancer Institute says nivolumab and ipilimumab “should be considered as a new standard of care” for patients with non-epithelioid mesothelioma. 

Both groups of patients had about the same number of serious complications. Three of the immunotherapy patients died as a result of the treatment. One of the chemotherapy patients died. 

This is the first randomized trial of dual immunotherapy as a first-line treatment for pleural mesothelioma. 

Sources:

“Opdivo (nivolumab) Plus Yervoy (ipilimumab) Demonstrates Durable Survival Benefit vs. Chemotherapy in Patients with Previously Untreated Malignant Pleural Mesothelioma”, Bristol Myers Squibb, Press Release, August 8, 2020, https://news.bms.com/press-release/corporatefinancial-news/opdivo-nivolumab-plus-yervoy-ipilimumab-demonstrates-durable-s

Fowler, Matthew, “Nivolumab Plus Ipilimumab Improves OS in Malignant Pleural Mesothelioma”, August 10, 2020, Cancer Network, https://www.cancernetwork.com/view/nivolumab-plus-ipilimumab-improves-os-in-malignant-pleural-mesothelioma

Similar Posts

  • | |

    Doctors Describe "Concrete Therapeutic Approach" for Mesothelioma

    ByAlex Strauss

    A team of medical researchers in Italy have achieved what they are calling “excellent” tumor control and survival results in malignant pleural mesothelioma patients using a combination of surgery, chemotherapy, and radiotherapy. Caused by exposure to asbestos, mesothelioma typically spreads quickly across the lung-encasing membrane called the pleura. There is no known cure but treatments are improving. In the current prospective study, 20 malignant pleural mesothelioma patients underwent radical pleurectomy/decortication followed by high doses of radiation. After surgeons removed as much of the visible mesothelioma tumor and surrounding tissue as possible, patients received 50Gy of radiation to the effected side of their chest, delivered in 25 fractions. Regions of particular concern for mesothelioma regrowth got an extra radiation “boost” to…

  • |

    Mesothelioma Still Rising Despite Ban in Ireland

    ByAlex Strauss

    A study in Ireland confirms that it can take many years for a ban on asbestos to have a measurable impact on a country’s rates of malignant mesothelioma. Mesothelioma is the most serious of a list of diseases – including lung cancer, pleural plaques, asbestosis, and others – linked with exposure to asbestos dust. Affecting the linings around the lungs and other organs, mesothelioma is often resistant to most cancer treatments and may be fatal within a year of diagnosis. According to the International Ban Asbestos Secretariat, Ireland is one of 55 countries that have enacted some type of asbestos ban. However, although Ireland banned asbestos in 2000, a new study published in Cancer Epidemiology shows that incidence of the…

  • | |

    Does Radiotherapy Reduce Mesothelioma Pain?

    ByAlex Strauss

    A new study says there is not enough evidence to support the use of radiotherapy for the treatment of pain associated with malignant pleural mesothelioma. Researchers at the University of Edinburgh in Scotland reviewed a range of past studies on mesothelioma pain and radiotherapy by searching databases that date back as far as 1974. To be eligible to be included in their review, the study had to focus on malignant pleural mesothelioma and radiotherapy given “with the intent of improving pain”. The study also had to report doses and fractionation of the radiotherapy and how the pain responded. In all, the researchers found eight studies on mesothelioma pain and radiotherapy that met the criteria. Two of the studies were prospective…

  • |

    Website Aims to Protect Homeowners from Mesothelioma

    ByAlex Strauss

    Australia’s Cancer Council is trying to educate home renovators about their risk for mesothelioma with a new e-learning course. Australia has one of the highest per capita rates of mesothelioma in the world, largely because of several asbestos mining operations that were once located there. Although asbestos has been banned from building products in Australia since 1989, asbestos-linked diseases like mesothelioma, lung cancer, and asbestosis continue to pose a serious health concern. While mesothelioma has traditionally occurred among people exposed to asbestos on the job, Australia is now bracing for another “wave” of mesothelioma victims among homeowners who encounter asbestos while doing their own renovation projects. Cancer Council Australia has launched “kNOw asbestos in your home” in an effort to…

  • |

    Ape Virus Shrinks Mesothelioma Tumors in Lab

    ByAlex Strauss

    A virus that causes leukemia in gibbon apes may have the power to help fight malignant mesothelioma in people. Gibbon ape leukemia virus (GALV) has been tested for years as a viral vector, a carrier of therapeutic genetic information, in the treatment of various human illnesses, including cancer. A new study in Japan compared GALV with a leukemia virus derived from mice to see which carrier communicated most efficiently with mesothelioma cells. While both types of viruses replicated in most of the mesothelioma cell lines tested, the mouse-derived virus was not effective in a mesothelioma cell line called ACC-MESO-1. In this cell line, only the GALV spread efficiently both in culture and in mice that had been given human mesothelioma…

  • | |

    Radiotherapy for Mesothelioma: Better But Still Limited

    ByAlex Strauss

    A form of highly-targeted radiation therapy for mesothelioma is better than it used to be, but is still risky. That is the message of a recent article on intensity-modulated radiation therapy (IMRT) in Seminars in Thoracic and Cardiovascular Surgery. Author Kenneth E. Rosenzweig, MD, a Radiation Oncologist with Mount Sinai Hospital in New York, reviewed recent studies on IMRT and mesothelioma. He concludes that, while the “troubling toxicity” associated with IMRT when it was first introduced has not been entirely eliminated, the fact that clinicians now have more experience with it is making a positive difference for mesothelioma patients. Before targeted therapies like IMRT were available, high-dose radiation was not usually a feasible option for mesothelioma since the irregular shape…